Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q4 FY20 Earnings Presentation
25 slides from Dishman Carbogen Amcis's earnings presentation, Jun 4, 2020
Slide 1: Cover letter to stock exchanges
4th June, 2020 To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, “Exchange Plaza”, C-1, Block G, Mumbai – 400 001. Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref.: Scrip Code No.
Slide 2: Q4 & FY20 Results Update
DISHMAN CARBOGEN AMCIS LIMITED Q4 & FY20 RESULTS UPDATE JUNE 2020 1
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward looking statements, which may include statements relating to future results of
Slide 4: Discussion Summary
DISCUSSION SUMMARY ❖ Q4 & FY20 RESULTS UPDATE ❖ INDUSTRY OVERVIEW ❖ COMPANY OVERVIEW 3
Slide 5: Q4 & FY20 Results Update
Q4 & FY20 RESULTS UPDATE 4
Slide 6: Q4 FY20 Result Highlights
Q4 FY20 RESULT HIGHLIGHTS In Rs Mn REVENUES EBITDA & EBITDA MARGIN * 6,497 26.1% 5,121 25.8% 1,694 1,319 Q4 FY19 Q4 FY20 Q4 FY19 Q4 FY20 ADJUSTED PBT # & PBT MARGIN CASH PAT @ & CASH EPS 19.7% 16.0% 9.0 7.0 1,446 1,280 1,129 819 Q4 FY19 Q4 FY20 Q4 FY19 Q4 FY20 @ Cash PAT = Adjusted PAT + (Depreciati
Slide 7: FY20 Result Highlights
FY20 RESULT HIGHLIGHTS In Rs Mn REVENUES EBITDA & EBITDA MARGIN * 20,586 20,436 26.8% 25.6% 5,519 5,224 FY19 FY20 FY19 FY20 ADJUSTED PBT # & PBT MARGIN CASH PAT @ & CASH EPS 19.3% 15.2% 27.9 26.5 4,499 4,273 3,972 3,105 FY19 FY20 FY19 FY20 @ Cash PAT = Adjusted PAT + (Depreciation – additional goodw
Slide 8: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (In Rs. Mn.) Q4 FY20 Q4 FY19 YoY % FY20 FY19 YoY % Revenue from Operations 5,028.3 6,114.2 -17.8% 19,732.6 19,199.4 2.8% Other Operating Income 92.9 383.0 -75.7% 703.4 1,386.6 -49.3% Total Revenues 5,121.2 6,497.2 -21.2% 20,436.0 20,586.0 -0.7% COGS 1,113.1 1,5
Slide 9: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET Particulars (Rs. Mn.) Mar-20 Mar-19 Particulars (Rs. Mn.) Mar-20 Mar-19 Shareholder Funds Non-Current Assets Equity Share Capital 313.8 322.8 Property, plant and equipment 17,118.5 15,330.3 Other Equity 57,063.0 53,468.1 Capital Work in Progress 2,023.4 1,433.3 Total – Sha
Slide 10: Q4 & FY20 Segment-wise Revenue Analysis
Q4 & FY20 SEGMENT-WISE REVENUE ANALYSIS In Rs Mn Revenues – Segment wise Breakup Q4 FY20 Q4 FY19 YoY% FY20 FY19 YoY% CRAMS (% of total) CRAMS – India 916.7 1,305.0 -29.8% 3,323.5 3,405.8 -2.4% CRAMS – Switzerland & France 2,783.2 3,131.2 -11.1% 10,815.3 10,396.2 4.0% CRAMS – UK 152.2 283.0 -46.2% 96
Slide 11: Segment-wise Revenue Break-up
SEGMENT-WISE REVENUE BREAK-UP Total Operating Revenue – Q4 FY20 Total Operating Revenue – FY20 CRAMS – 76.6% Marketable Molecules – 23.4% CRAMS – 76.5% Marketable Molecules – 23.5% 4% 6% 55% 54% 72% 72% 100% 100% 45% 46% 24% 22% CRAMS - India CRAMS - Switzerland & France CRAMS - India CRAMS - Switze
Slide 12: Q4 & FY20 Segment-wise Margin Analysis
Q4 & FY20 SEGMENT-WISE MARGIN ANALYSIS EBITDA Margin % – Segment wise Q4 FY20 Q4 FY19 FY20 FY19 CRAMS CRAMS – India 53.4% 53.0% 55.5% 57.1% CRAMS – Switzerland & France 20.8% 21.0% 20.4% 19.8% CRAMS – UK 14.4% 14.0% 16.4% 24.1% Marketable Molecules Carbogen Amcis BV 26.9% 27.0% 32.0% 40.9% Others 10
Slide 13: Q4 & FY20 Result Highlights
Q4 & FY20 RESULT HIGHLIGHTS Financial Highlights: ❑ Total Revenues at Rs 5,121.2 mn in Q4 FY 2020 down by 21.2% YoY ❖ CRAMS revenue decreased 18.4% YoY primarily due to : ❖ CRAMS Carbogen Amcis AG revenue decreased by 11 %, attributable to higher revenues in the preceding quarters and certain commer
Slide 14: Q4 & FY20 Result Highlights
Q4 & FY20 RESULT HIGHLIGHTS ❑Net debt as on March 31, 2020 stands at USD 100 mil vs USD 120 mil March 31, 2019 ❑Finished goods inventory maintained at a higher level in Carbogen Amcis AG to fulfil the commercial product sales in upcoming quarters ❑Capital expenditure for FY 2020 was approximately US
Slide 15: Company Overview
COMPANY OVERVIEW 14
Slide 16: Brief Profile
BRIEF PROFILE BUSINESS OVERVIEW KEY STRENGTHS FINANCIAL OVERVIEW • Integrated CRAMS company with strong • Preferred global outsourcing partner with • Consolidated Revenues, EBITDA and capabilities right from process research & capabilities across the entire CRAMS value Adj. PAT of Rs 20,436 Mn, Rs 5
Slide 17: Manufacturing Facilities – Robust R&D Capabilities
MANUFACTURING FACILITES – ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: USFDA, MEB, SWISS MEDIC, ANSM, TGA, WHO, KFDA Superior Chemistry Skills & Capabilities • 28 dedicated R&D labs with multiple-shift R&D operations, including HIPO labs • 25 multi-purpose facilitie
Slide 18: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER INTEGRATED STRONG CLOSE PROXIMITY LARGE SCALE ACROSS THE VALUE CHEMISTRY TO CLIENTS WITH MANUFACTURING CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 19: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER Integrated CRAMS Player – Strong Capabilities across the Value Chain Carbogen Amcis (CA) Strong Research Capabilities EARLY STAGE LATE STAGE COMMERCIAL SUPPLY • Focus is on supporting the Process research and API supply to Process development and Secure, value-for-money devel
Slide 20: Cutting-Edge HIPO Capabilities
CUTTING-EDGE HIPO CAPABILITIES World Class HIPO capabilities • Facilities range from laboratory scale for process research and development to large scale manufacturing on 8,000 L scale, with an ability to handle the highest category IV compounds (high toxicity levels). • State-of-the-art containment
Slide 21: Industry Overview
INDUSTRY OVERVIEW 20
Slide 22: Global Spending on Medicine
GLOBAL SPENDING ON MEDICINE As per BRC Report, Contract Research Outsourcing (CRO) Market to reach $44.4bn by 2021 • Oncology is expected to be the most critical therapeutic segment driving the global spend on medicine in future. Outlook of Leading Therapy Areas Spending and Growth, Constant US $ Bn
Slide 23: Global Medicines in Late Stage Development
GLOBAL MEDICINES IN LATE STAGE DEVELOPMENT Oncology 29% • Oncology has become one of the major focus 13% areas for pharmaceutical and biotechnology companies. CNS 11% 7% • Around 29% of the Phase II / III clinical trials are in the Oncology segment. Anti-Infectives / 6% Antivirals 9% • Oncology (can
Slide 24: Global Oncology Medicine Pipeline
GLOBAL ONCOLOGY MEDICINE PIPELINE ➢ 710 Molecules in late-stage development and 700+ companies with late-stage oncology drugs. ➢ Top companies with combined sales of $10bn+ have ~40% of their product pipeline in oncology. ➢ 455 smaller companies with 90%+ product pipeline in oncology, are involved i
Slide 25: For Further Queries
FOR FURTHER QUERIES: Mr. Harshil Dalal Group CFO Email: harshil.dalal@dishmangroup.com Mr. Nachiket Kale / Chintan Mehta IR Consultants Contact: +91 9920940808 / +91 9892183389 Email:dishman@dickensonworld.com 24
Dishman Carbogen Amcis — Q4 FY20 Earnings Presentation on 6ix